DelveInsight’s, “Metastatic Hepatocellular Carcinoma Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Metastatic Hepatocellular Carcinoma pipeline landscape. It covers the Metastatic Hepatocellular Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Metastatic Hepatocellular Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Metastatic Hepatocellular Carcinoma research. Learn more about our innovative pipeline today! @ Metastatic Hepatocellular Carcinoma Pipeline Outlook
Key Takeaways from the Metastatic Hepatocellular Carcinoma Pipeline Report
Stay informed about the cutting-edge advancements in Metastatic Hepatocellular Carcinoma treatments. Download for updates and be a part of the revolution in cancer care @ Metastatic Hepatocellular Carcinoma Clinical Trials Assessment
Metastatic Hepatocellular Carcinoma Emerging Drugs Profile
CS1003 or Nofazinlimab is a humanized recombinant IgG4 monoclonal antibody targeting human programmed cell death protein 1 (PD-1) being developed in solid tumors. Nofazinlimab shows comparable high binding affinities to the PD-1 of humans, cynomolgus monkey, and mouse, and can block the interaction of PD-1 with its ligands PD-L1 and PD-L2. The U.S. FDA has granted nofazinlimab Orphan Drug Designation (ODD) in July 2020 for the treatment of patients with HCC. CStone formed a strategic collaboration agreement with EQRx, under which EQRx licensed the exclusive rights to two immuno-oncology assets, sugemalimab and nofazinlimab, for development and commercialization outside of Greater China. CStone retains rights to nofazinlimab in Greater China, where it can continue to pursue development as a monotherapy or as part of its combination strategy for this drug. Currently, the drug is in Phase III stage of its development for the treatment of hepatocellular carcinoma.
Casdozokitug is a human anti-IL-27 antibody designed to inhibit the activity of this immune regulatory cytokine. The company is focused on developing casdozokitug in particular tumor types where IL-27 secreted from macrophages appears to play an important role in the immunosuppressive tumor microenvironment and may contribute to resistance to treatment with immune checkpoint inhibitors. Preclinical studies have shown that treatment with casdozokitug blocks the immunosuppressive biologic effects of IL-27, resulting in immune cell activation in combination with other cancer therapies including anti-PD-1 therapy, as well as anti-tumor effects. Casdozokitug has been granted Orphan Drug designation and Fast Track designation for the treatment of refractory hepatocellular carcinoma from the FDA. It is the first IL-27 antibody to enter the clinic. Currently, the drug is in Phase II stage of its development for the treatment of hepatocellular carcinoma.
TTI-101 is an orally bioavailable, small-molecule inhibitor of signal transducer and activator of transcription 3 (STAT3), a transcription factor whose upregulation and activation governs many hallmarks of cancer, inflammation, and fibrosis. Preclinically, TTI-101 has demonstrated an excellent pharmacokinetic profile, potency in inhibiting STAT3 activation, and efficacy in inhibiting tumor growth in xenograft and syngeneic tumor models. In its first-in-man Phase 1 trial conducted in patients with relapsed/refractory tumors, TTI-101 monotherapy was well-tolerated and had clinical activity across a broad range of tumors including multiple durable radiographic objective responses. Currently, the drug is in Phase I/II stage of its development for the treatment of hepatocellular carcinoma.
ST316, a first-in-class antagonist of the interaction between β-catenin and its co-activator BCL9, is being evaluated in the Phase I portion of a Phase I-II clinical study in patients with selected advanced unresectable and metastatic solid tumors. ST316-101 is an open-label, two-part study. The Phase I dose-escalation portion of the study is designed to determine the safety, tolerability, PK, and PD of ST316 in patients with selected advanced solid tumors likely to harbor abnormalities of the Wnt/β-catenin signaling pathway. The Phase II dose-expansion portion aims to continue to assess the safety of ST316 as well as proof of concept in four specific tumor types known to harbor abnormalities of the Wnt/β-catenin signaling pathway. Currently, the drug is in Phase I/II stage of its development for the treatment of hepatocellular carcinoma.
The Metastatic Hepatocellular Carcinoma Pipeline report provides insights into
Learn more about Metastatic Hepatocellular Carcinoma Drugs opportunities in our groundbreaking Metastatic Hepatocellular Carcinoma research and development projects @ Metastatic Hepatocellular Carcinoma Unmet Needs
Metastatic Hepatocellular Carcinoma Companies
Ionis Pharmaceuticals, CStone Pharmaceuticals, Coherus BioSciences, Tvardi Therapeutics, Sapience Therapeutics, Inc., Eureka Therapeutics Inc., Krystal Biotech, Inc., Replimune Inc., Beijing Syngentech Co., Ltd., Boehringer Ingelheim, AbbVie, Chugai Pharmaceutical, GenVivo, Inc., Suzhou Kintor Pharmaceutical Inc., Shanghai Henlius Biotech and others.
Metastatic Hepatocellular Carcinoma Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Metastatic Hepatocellular Carcinoma Products have been categorized under various Molecule types such as
Discover the latest advancements in Metastatic Hepatocellular Carcinoma treatment by visiting our website. Stay informed about how we’re transforming the future of oncology @ Metastatic Hepatocellular Carcinoma Market Drivers and Barriers, and Future Perspectives
Scope of the Metastatic Hepatocellular Carcinoma Pipeline Report
For a detailed overview of our latest research findings and future plans, read the full details of Metastatic Hepatocellular Carcinoma Pipeline on our website @ Metastatic Hepatocellular Carcinoma Emerging Drugs and Companies
Table of Contents
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/report-store/metastatic-hepatocellular-carcinoma-pipeline-insight